Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics, Inc. has announced the publication of an abstract for its radiopharmaceutical therapy, PPMX-T002, aimed at treating solid cancers, at the EANM ’24 Annual Congress. PPMX-T002 targets the cadherin 3 protein on various solid tumors and has shown enhanced efficacy in preclinical trials when using Actinium 225 compared to Yttrium 90.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.